Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 9월 2024 - 10:00AM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
reported the grant of an aggregate of 10,845 restricted stock units
(RSUs) of the company’s common stock to 5 newly hired non-executive
employees of the company. The awards were approved by the
compensation committee of the company’s board of directors under
the Evolus’ 2023 Inducement Incentive Plan, with a grant date of
September 12, 2024, and a vesting commencement date of September 7,
2024, as an inducement material to the new employees entering into
employment with Evolus in accordance with Nasdaq Listing Rule
5635(c)(4).
The RSUs vest 25% on each annual anniversary of the vesting
commencement date. The awards are subject to the terms and
conditions of the 2023 Inducement Incentive Plan and the terms and
conditions of RSU agreement covering the grant, including
requirements to remain continuously employed on each vesting
date.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company
evolving the aesthetic neurotoxin market for the next generation of
beauty consumers through its unique, customer-centric business
model and innovative digital platform. Our mission is to become a
global, multi-product aesthetics company based on our flagship
product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only
neurotoxin dedicated exclusively to aesthetics and manufactured in
a state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, and
the exclusive distributor in Europe of Estyme®, a line of unique
dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, X,
Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™
is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong
Pharmaceutical Co, Ltd. Estyme® is a trademark of Symatese
Aesthetics S.A.S.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240927335094/en/
Evolus Contacts: Investors: Nareg
Sagherian Vice President, Head of Global Investor Relations and
Corporate Communications Tel: 248-202-9267 Email: ir@evolus.com
Media: Email: media@evolus.com
Evolus (NASDAQ:EOLS)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Evolus (NASDAQ:EOLS)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
